Comparing the current results to its competitors, Inmune Bio Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 26.96 %, recorded in the same quarter.
Inmune Bio Inc 's Comment on Competition and Industry Peers
In the European Union, innovative medicinal products classified as New Chemical Entities (NCEs) receive eight years of data exclusivity and ten years of marketing exclusivity. An additional one-year marketing exclusivity may be granted under specific conditions. These exclusivity periods can delay the entry of generic, hybrid, or biosimilar competitors.
September 13, 2024
: In a significant move to bolster its financial resources and advance its pioneering treatments, INmune Bio Inc. (Nasdaq: INMB) has successfully closed a $13.0 million registered direct offering. This capital influx is set to fortify the company s ongoing work in tackling inflammation and immunology through the enhancement of patients innate immune systems.INmune Bio Inc. a clinical-stage company centered around inflammation and immunology, has revealed a successful closure of a $13.0 million registered direct offering. By entering into securities purchase agreements with both new and existing institutional investors, as well as insiders of the company, INmune Bio aims to escalate its development of innova...
June 27, 2024
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer s Disease TrialIn a recent press release, INmune Bio, Inc. announced the completion of a blinded interim analysis of their Phase II clinical trial for Alzheimer s disease. The results of this analysis have confirmed the accuracy of the sample size calculations and statistical power for the primary endpoint, EMACC (Early Memory and Cognition Composite).Alzheimer s disease is a devastating neurodegenerative disorder that affects millions of individuals worldwide. Finding a successful treatment for this condition has proven to be an immense challenge, but INmune Bio, Inc. is dedicated to developing innovative therapies to make a differenc...
Black Diamond Therapeutics Inc's business model is centered around developing targeted therapies for cancer patients by leveraging its proprietary platform and expertise in precision medicine.
Ionis Pharmaceuticals Inc is a biopharmaceutical company that operates on a two-fold business model. Firstly, the company focuses on discovering and developing antisense drugs, utilizing a unique RNA-targeted technology. Secondly, Ionis collaborates with established pharmaceutical partners to license and commercialize their drugs, allowing for maximum reach and potential commercial success.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Neurocrine Biosciences Inc's business model involves researching, developing, and commercializing innovative therapies for neurological and endocrine disorders.
Sources:
Inmune Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Inmune Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
